Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
This article was originally published in The Gray Sheet
Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.
You may also be interested in...
Benefits to test makers and users from the Medicare MolDx program have not been fully reaped, diagnostic reimbursement experts said at a recent Avalere summit.
In this second portion of a two-part Q&A with Louis Jacques, he talks to “The Gray Sheet” about the importance of CMS’ growing collaboration with FDA, tensions between national and local Medicare coverage policymaking and the impact of resource constraints on CMS. Jacques left his post as CMS coverage director last month.
CMS has extended the comment period on its nearly 50 percent BRCA testing reimbursement cut to the end of February. But comments from lab and diagnostics groups so far try to underscore the “capriciousness and lack of transparency” that CMS displayed when it made the cut. Experts say the agency is unlikely to change its mind.